LIVIVO - Search results -

Search results

Result 1 - 10 of total 12

Search options

Article ; Online: Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 -2020).

Bartels, Sanne A L / van Olmen, Josefien P / Scholten, Astrid N / Bekers, Elise M / Drukker, Caroline A / Vrancken Peeters, Marie-Jeanne T F D / van Duijnhoven, Frederieke H

European journal of cancer (Oxford, England : 1990)

2024 Volume 201, Page(s) 113924

Abstract: Aim: The aim of our study is to analyze patterns in treatment and outcome in a population-based series of patients with borderline and malignant phyllodes tumors (PT).: Material and methods: Data on all patients with a borderline or malignant PT ( ... ...

Abstract	Aim: The aim of our study is to analyze patterns in treatment and outcome in a population-based series of patients with borderline and malignant phyllodes tumors (PT). Material and methods: Data on all patients with a borderline or malignant PT (1989-2020) were extracted from the Netherlands Cancer Registry and the Dutch nationwide pathology databank (Palga) and retrospectively analyzed. Results: We included 921 patients (borderline PT n = 452 and malignant PT n = 469). Borderline PT patients more often had breast-conserving surgery (BCS) as final surgery (81 vs. 46%). BCS rates for borderline PT increased over time (OR 1.08 per year, 95%CI 1.04 - 1.13, P < 0.001). In malignant PT adjuvant radiotherapy was given in 14.7%; this rate increased over time (OR 1.07 per year, 95%CI 1.02 - 1.13, P = 0.012). Local recurrence rate (5-year estimate of cumulative incidence) was 8.7% (95%CI 6.0-11.4) for borderline PT and 11.7% (95%CI 8.6-14.8) for malignant PT (P = 0.187) and was related to tumor size ≥ 20 mm (HR 10.6 (95%CI 1.5-76.8) and positive margin (HR 3.0 (95%CI 1.6-5.6), p < 0.001), but not to negative margin width (HR 1.3 ( 95%CI 0.7-2.3), p = 0.350)). Distant metastasis occurred only in malignant PT with a 5-year cumulative incidence of 4.7% (95%CI 3.3 - 6.1). Conclusion: This population-based series showed an increase in BCS in borderline PT and an increase in adjuvant radiotherapy in malignant PT over time. We identified malignant PT, BCS, larger tumor size and positive final margins as possible risk factors for local recurrence. Small but negative margins can be accepted.
MeSH term(s)	Humans ; Female ; Mastectomy ; Phyllodes Tumor/epidemiology ; Phyllodes Tumor/surgery ; Phyllodes Tumor/pathology ; Retrospective Studies ; Netherlands/epidemiology ; Follow-Up Studies ; Neoplasm Recurrence, Local/pathology ; Margins of Excision ; Breast Neoplasms/epidemiology ; Breast Neoplasms/surgery
Language	English
Publishing date	2024-02-10
Publishing country	England
Document type	Journal Article
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2024.113924
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.

van Olmen, Josefien P / Jacobs, Chaja F / Bartels, Sanne A L / Loo, Claudette E / Sanders, Joyce / Vrancken Peeters, Marie-Jeanne T F D / Drukker, Caroline A / van Duijnhoven, Frederieke H / Kok, Marleen

Breast (Edinburgh, Scotland)

2024 Volume 75, Page(s) 103726

Abstract: Objective: This study aims to evaluate the response to and surgical benefits of neoadjuvant endocrine therapy (NET) in ER+/HER2-breast cancer patients who are clinically high risk, but genomic low risk according to the 70-gene signature (MammaPrint).: ...

Abstract	Objective: This study aims to evaluate the response to and surgical benefits of neoadjuvant endocrine therapy (NET) in ER+/HER2-breast cancer patients who are clinically high risk, but genomic low risk according to the 70-gene signature (MammaPrint). Methods: Patients with ER+/HER2-invasive breast cancer with a clinical high risk according to MINDACT, who had a genomic low risk according to the 70-gene signature and were treated with NET between 2015 and 2023 in our center, were retrospectively analyzed. RECIST 1.1 criteria were used to assess radiological response using MRI or ultrasound. Surgical specimens were evaluated to assess pathological response. Two breast cancer surgeons independently scored the eligibility of breast conserving therapy (BCS) pre- and post- NET. Results: Of 72 included patients, 23 were premenopausal (100% started with tamoxifen of which 4 also received OFS) and 49 were postmenopausal (98% started with an aromatase inhibitor). Overall, 8 (11%) showed radiological complete response. Only 1 (1.4%) patient had a pathological complete response (RCB-0) and 68 (94.4%) had a pathological partial response (RCB-1 or RCB-2). Among the 26 patients initially considered for mastectomy, 14 (53.8%) underwent successful BCS. In all 20 clinical node-positive patients, a marked axillary lymph node was removed to assess response. Four out of 20 (20%) patients had a pathological complete response of the axilla. Conclusion: The study showed that a subgroup of patients with a clinical high risk and a genomic low risk ER+/HER2-breast cancer benefits from NET resulting in BCS instead of a mastectomy. Additionally, NET may enable de-escalation in axillary treatment.
MeSH term(s)	Humans ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/surgery ; Breast Neoplasms/therapy ; Female ; Neoadjuvant Therapy/methods ; Middle Aged ; Retrospective Studies ; Receptor, ErbB-2/metabolism ; Receptor, ErbB-2/analysis ; Adult ; Receptors, Estrogen/metabolism ; Receptors, Estrogen/analysis ; Antineoplastic Agents, Hormonal/therapeutic use ; Aged ; Tamoxifen/therapeutic use ; Mastectomy, Segmental/methods ; Aromatase Inhibitors/therapeutic use ; Magnetic Resonance Imaging ; Treatment Outcome
Chemical Substances	ERBB2 protein, human
Language	English
Publishing date	2024-04-05
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1143210-x
ISSN	1532-3080 ; 0960-9776
ISSN (online)	1532-3080
ISSN	0960-9776
DOI	10.1016/j.breast.2024.103726
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3620: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 588: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort.

Lopes Cardozo, Josephine M N / Veira, Sherylene E / Ait Hassou, Laila / Uwimana, Aimé Lambert / Božović-Spasojević, Ivana / Bogaerts, Jan / Cardoso, Fatima / Schmidt, Marjanka K / Rutgers, Emiel J T / Poncet, Coralie / Drukker, Caroline A

Breast (Edinburgh, Scotland)

2023 Volume 71, Page(s) 143–149

Abstract: Purpose: Tailored recommendation for adjuvant chemotherapy in breast cancer patients is of great importance. This survey assessed agreement among oncologists on risk assessment and chemotherapy recommendation, the impact of adding the 70-gene signature ... ...

Abstract	Purpose: Tailored recommendation for adjuvant chemotherapy in breast cancer patients is of great importance. This survey assessed agreement among oncologists on risk assessment and chemotherapy recommendation, the impact of adding the 70-gene signature to clinical-pathological characteristics, and changes over time. Methods: A survey consisting of 37 discordant patient cases from the MINDACT trial (T1-3N0-1M0) was sent to European breast cancer specialists for assessment of risk (high or low) and chemotherapy administration (yes or no). In 2015 the survey was sent twice (survey 1 and 2), several weeks apart, and in 2021 a third time (survey 3). Only the second and third surveys included the 70-gene signature result. Results: 41 breast cancer specialists participated in all three surveys. Overall agreement between respondents decreased slightly between survey 1 and 2, but increased again in survey 3. Over time there was an increase in agreement with the 70-gene signature result on risk assessment, 23% in survey 2 versus 1 and 11% in survey 3 versus 2. With information available indicating a low risk 70-gene signature (n = 25 cases), 20% of risk assessments changed from high to low and 19% of recommendations changed from yes to no chemotherapy in survey 2 versus 1, further increasing with 18% and 21%, respectively, in survey 3 versus 2. Conclusion: There is a variability in risk assessment of early breast cancer patients among breast cancer specialists. The 70-gene signature provided valuable information, resulting in fewer patients being assessed as high risk and fewer recommendations for chemotherapy, increasing over time.
MeSH term(s)	Female ; Humans ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Risk Assessment/methods ; Surveys and Questionnaires ; Clinical Trials as Topic
Language	English
Publishing date	2023-05-18
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1143210-x
ISSN	1532-3080 ; 0960-9776
ISSN (online)	1532-3080
ISSN	0960-9776
DOI	10.1016/j.breast.2023.05.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3620: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 588: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Management of Benign Phyllodes Tumors: A Dutch Population-Based Retrospective Cohort Between 1989 and 2022.

van Olmen, Josefien P / Beerthuizen, Annemijn W J / Bekers, Elise M / Viegen, Isabella / Drukker, Caroline A / Vrancken Peeters, Marie-Jeanne T F D / Bartels, Sanne A L / van Duijnhoven, Frederieke H

Annals of surgical oncology

2023 Volume 30, Issue 13, Page(s) 8344–8352

Abstract: Background: Phyllodes tumors (PTs) are rare tumors of the breast. The current National Comprehensive Cancer Network (NCCN) guidelines recommend excision of benign PTs, accepting close or positive margins. Controversy about the optimal treatment for ... ...

Abstract	Background: Phyllodes tumors (PTs) are rare tumors of the breast. The current National Comprehensive Cancer Network (NCCN) guidelines recommend excision of benign PTs, accepting close or positive margins. Controversy about the optimal treatment for benign PTs remains, especially regarding the preferred margin width after surgical excision and the need for follow-up evaluation. Methods: A nationwide retrospective study analyzed the Dutch population from 1989 to 2022. All patients with a diagnosis of benign PT were identified through a search in the Dutch nationwide pathology databank (Palga). Information on age, year of diagnosis, size of the primary tumor, surgical treatment, surgical margin status, and local recurrence was collected. Results: The study enrolled 1908 patients with benign PT. The median age at diagnosis was 43 years (interquartile range [IQR], 34-52 years), and the median tumor size was 30 mm (IQR, 19-40 mm). Most of the patients (95%) were treated with breast-conserving surgery (BCS). The overall local recurrence rate was 6.2%, and the median time to local recurrence was 31 months (IQR, 15-61 months). Local recurrence was associated with bilaterality of the tumor (odds ratio [OR], 4.91; 95% confidence interval [CI], 2.95-28.30) and positive margin status (OR, 2.51; 95% CI 1.36-4.63). The local recurrence rate was 8.9% for the patients with positive excision margins and 4.0% for the patients with negative excision margins. Notably, for 27 patients (22.6%) who experienced a local recurrence, histologic upgrading of the recurrent tumor was reported, 7 (5.9%) of whom had recurrence as malignant lesions. Conclusions: This nationwide series of 1908 patients showed a low local recurrence rate of 6.2% for benign PT, with higher recurrence rates following positive margins.
MeSH term(s)	Humans ; Adult ; Middle Aged ; Female ; Phyllodes Tumor/pathology ; Retrospective Studies ; Margins of Excision ; Neoplasm Recurrence, Local/pathology ; Breast Neoplasms
Language	English
Publishing date	2023-08-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	1200469-8
ISSN	1534-4681 ; 1068-9265
ISSN (online)	1534-4681
ISSN	1068-9265
DOI	10.1245/s10434-023-14128-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4042: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.

Lopes Cardozo, Josephine M N / Drukker, Caroline A / Rutgers, Emiel J T / Schmidt, Marjanka K / Glas, Annuska M / Witteveen, Anke / Cardoso, Fatima / Piccart, Martine / Esserman, Laura J / Poncet, Coralie / van 't Veer, Laura J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022 Volume 40, Issue 12, Page(s) 1335–1345

Abstract: Purpose: Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. The ultralow-risk subgroup was characterized to help avoid overtreatment. We evaluated outcomes of ... ...

Abstract	Purpose: Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. The ultralow-risk subgroup was characterized to help avoid overtreatment. We evaluated outcomes of ultralow-risk patients in the largest cohort to date. Methods: Of the 6,693 patients enrolled in the EORTC-10041/BIG-3-04 randomized phase III MINDACT trial, profiling revealed an ultralow-risk 70-gene signature in 1,000 patients (15%). Distant metastasis-free interval (DMFI) and breast cancer-specific survival (BCSS) were assessed in patients stratified by 70-gene signature result (high, low, and ultralow) by Kaplan-Meier analysis and hazard ratios with 95% CI from Cox regression. Results: Median follow-up was 8.7 years. Of the ultralow-risk patients (n = 1,000), 67% were > 50 years, 81% had tumors ≤ 2 cm, 80% were lymph node-negative, 96% had grade 1 or 2 tumors, and 99% were estrogen receptor (ER)-positive. Systemic therapy was received by 84% of patients (69% endocrine therapy, 14% endocrine therapy plus chemotherapy, 1% other) and 16% received no adjuvant systemic treatment. The 8-year DMFI for ultralow-risk patients was 97.0% (95% CI, 95.8 to 98.1), which was 2.5% higher than for patients with low-risk tumors (n = 3,295, 94.5% [95% CI, 93.6 to 95.3]). The hazard ratio for DMFI was 0.65 (95% CI, 0.45 to 0.94) for ultralow versus low risk, after adjusting for clinical-pathologic and treatment characteristics. The 8-year BCSS for ultralow-risk patients was 99.6% (95% CI, 99.1 to 100). Conclusion: Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.
MeSH term(s)	Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Chemotherapy, Adjuvant ; Female ; Humans ; Kaplan-Meier Estimate ; Prognosis ; Proportional Hazards Models
Language	English
Publishing date	2022-01-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.21.02019
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Long-Term Oncological Outcomes of Papillary Thyroid Cancer and Follicular Thyroid Cancer in Children: A Nationwide Population-Based Study.

van de Berg, Daniël J / Kuijpers, Anke M J / Engelsman, Anton F / Drukker, Caroline A / van Santen, Hanneke M / Terwisscha van Scheltinga, Sheila C E J / van Trotsenburg, A S Paul / Mooij, Christiaan F / Vriens, Menno R / Nieveen van Dijkum, Els J M / Derikx, Joep P M

Frontiers in endocrinology

2022 Volume 13, Page(s) 899506

Abstract: Introduction: Pediatric thyroid carcinoma is a rare malignancy and data on long-term oncological outcomes are sparse. The aim of this study was to describe the long-term oncological outcomes of pediatric papillary thyroid carcinoma (PTC) and follicular ... ...

Abstract	Introduction: Pediatric thyroid carcinoma is a rare malignancy and data on long-term oncological outcomes are sparse. The aim of this study was to describe the long-term oncological outcomes of pediatric papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) in a national cohort, and to identify risk factors for recurrence. Methods: We conducted a nationwide, retrospective cohort study, in which we combined two national databases. Patients aged <18 years, diagnosed with PTC or FTC in the Netherlands between 2000 and 2016, were included. pT-stage, pN-stage, multifocality and angioinvasion were included in a Cox-regression analysis for the identification of risk factors for recurrence. Results: 133 patients were included: 110 with PTC and 23 with FTC. Patients with PTC most often presented with pT2 tumors (24%) and pN1b (45%). During a median follow-up of 11.3 years, 21 patients with PTC developed a recurrence (19%). Nineteen recurrences were regional (91%) and 2 were pulmonary (9%). No risk factors for recurrence could be determined. One patient who developed pulmonary recurrence died two years later. Cause of death was not captured. Patients with FTC most often presented with pT2 tumors (57%). One patient presented with pN1b (4%). In 70%, no lymph nodes were collected. None of the patients with FTC developed a recurrence or died. Conclusion: Pediatric PTC and FTC are two distinct diseases. Recurrence in pediatric PTC is common, but in FTC it is not. Survival for both pediatric PTC and FTC is very good.
MeSH term(s)	Adenocarcinoma, Follicular/diagnosis ; Carcinoma, Papillary/pathology ; Child ; Humans ; Retrospective Studies ; Thyroid Cancer, Papillary/epidemiology ; Thyroid Neoplasms/diagnosis ; Thyroid Neoplasms/epidemiology ; Thyroid Neoplasms/therapy
Language	English
Publishing date	2022-05-04
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2592084-4
ISSN	1664-2392
ISSN	1664-2392
DOI	10.3389/fendo.2022.899506
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.

Vliek, Sonja B / Hilbers, Florentine S / Jager, Agnes / Retèl, Valesca P / Bueno de Mesquita, Jolien M / Drukker, Caroline A / Veltkamp, Sanne C / Zeillemaker, Anneke M / Rutgers, Emiel J / van Tinteren, Harm / van Harten, Wim H / van 't Veer, Laura J / van de Vijver, Marc J / Linn, Sabine C

European journal of cancer (Oxford, England : 1990)

2022 Volume 175, Page(s) 169–179

Abstract: Introduction: Prognostic gene expression signatures can be used in combination with classical clinicopathological factors to guide adjuvant chemotherapy decisions in ER-positive, HER2-negative breast cancer. However, long-term outcome data after ... ...

Abstract	Introduction: Prognostic gene expression signatures can be used in combination with classical clinicopathological factors to guide adjuvant chemotherapy decisions in ER-positive, HER2-negative breast cancer. However, long-term outcome data after introduction of genomic testing in the treatment decision-making process are limited. Methods: In the prospective RASTER study, the tumours of 427 patients with cTanyN0M0 breast cancer were tested to assess the 70-gene signature (MammaPrint). The results were provided to their treating physician to be incorporated in the decision-making on adjuvant systemic therapy. Here, we report the long-term outcome of the 310 patients with ER-positive, HER2-negative tumours by clinical and genomic risk categories at a median follow-up of 10.3 years. Results: Among the clinically high-risk patients, 45 (49%) were classified as genomically low risk. In this subgroup, at 10 years, distant recurrence free interval (DRFI) was similar between patients treated with (95.7% [95% CI 87.7-100]) and without (95.5% [95% CI 87.1-100]) chemotherapy. Within the group of clinically low-risk patients, 56 (26%) were classified as genomically high risk. Within the clinically low-risk group, beyond 5 years, a difference emerged between the genomically high- and low-risk subgroup resulting in a 10-year DRFI of 84.3% (95% CI 74.8-95.0) and 93.4% (95% CI 89.5-97.5), respectively. Interestingly, genomic ultralow-risk patients have a 10-year DRFI of 96.7% (95% CI 90.5-100), largely (79%) without systemic therapy. Conclusions: These data confirm that clinically high-risk, genomically low-risk tumours have an excellent outcome in the real-world setting of shared decision-making. Together with the updated results of the MINDACT trial, these data support the use of the MammaPrint, in ER-positive, HER2-negative, node-negative, clinically high-risk breast cancer patients. Registry: ISRCTN71917916.
MeSH term(s)	Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Prognosis ; Prospective Studies ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism
Chemical Substances	Receptor, ErbB-2 (EC 2.7.10.1)
Language	English
Publishing date	2022-09-17
Publishing country	England
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2022.07.036
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

Article ; Online: Nut van genexpressieprofielen voor prognose borstkanker.

Drukker, Caroline A / Schmidt, Marjanka K / van Dalen, Thijs / van der Hoeven, Jacobus J M / Linn, Sabine C / Rutgers, Emiel J T

Nederlands tijdschrift voor geneeskunde

2014 Volume 158, Page(s) A7001

Abstract: Gene expression classifiers such as the 70-gene signature that reflect the biology of breast tumours have started to find their way into daily clinical practice. Several retrospective validation studies in breast cancer have established the prognostic ... ...

Title translation	Gene expression classifiers in the prognosis of breast cancer.
Abstract	Gene expression classifiers such as the 70-gene signature that reflect the biology of breast tumours have started to find their way into daily clinical practice. Several retrospective validation studies in breast cancer have established the prognostic value of the 70-gene signature (MammaPrint). The prospective observational RASTER study shows excellent 5-year distant recurrence-free intervals in 98.4% of patients who had a high clinical risk but who according to the 70-gene signature had a low risk. Particularly in patients aged 45 years or older with an oestrogen receptor (ER)-positive, HER2-negative tumour, diameter 1-2 cm, grade 2 there is prospective evidence that the 70-gene signature can make a useful contribution towards decision-making on adjuvant chemotherapy.
MeSH term(s)	Age Factors ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Outcome Assessment (Health Care) ; Prognosis ; Prospective Studies ; Receptors, Estrogen/metabolism ; Retrospective Studies ; Risk Assessment ; Survival Analysis
Chemical Substances	Receptors, Estrogen
Language	Dutch
Publishing date	2014
Publishing country	Netherlands
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A breast cancer gene signature for indolent disease.

Delahaye, Leonie J M J / Drukker, Caroline A / Dreezen, Christa / Witteveen, Anke / Chan, Bob / Snel, Mireille / Beumer, Inès J / Bernards, Rene / Audeh, M William / Van't Veer, Laura J / Glas, Annuska M

Breast cancer research and treatment

2017 Volume 164, Issue 2, Page(s) 461–466

Abstract: Purpose: Early-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to ... ...

Abstract	Purpose: Early-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to chemotherapy, long-term adherence may be low due to potential adverse side effects as well as compliance fatigue. It is of high clinical utility to identify subgroups of breast cancer patients who may have excellent long-term survival without or with limited duration of endocrine therapy to aid in personalizing endocrine treatment. Methods: We describe a new ultralow risk threshold for the 70-gene signature (MammaPrint) that identifies a group of breast cancer patients with excellent 20 year, long-term survival prognosis. Tumors of these patients are referred to as "indolent breast cancer." We used patient series on which we previously established and assessed the 70-gene signature high-low risk threshold. Results: In an independent validation cohort, we show that patients with indolent breast cancer had 100% breast cancer-specific survival at 15 years of follow-up. Conclusions: Our data indicate that patients with indolent disease may be candidates for limited treatment with adjuvant endocrine therapy based on their very low risk of distant recurrences or death of breast cancer.
MeSH term(s)	Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Cohort Studies ; Female ; Gene Regulatory Networks ; Genetic Predisposition to Disease ; Humans ; Kaplan-Meier Estimate ; Precision Medicine ; Prognosis ; Risk Assessment ; Survival Rate
Language	English
Publishing date	2017-04-27
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	604563-7
ISSN	1573-7217 ; 0167-6806
ISSN (online)	1573-7217
ISSN	0167-6806
DOI	10.1007/s10549-017-4262-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Obesity-associated changes in molecular biology of primary breast cancer.

Nguyen, Ha-Linh / Geukens, Tatjana / Maetens, Marion / Aparicio, Samuel / Bassez, Ayse / Borg, Ake / Brock, Jane / Broeks, Annegien / Caldas, Carlos / Cardoso, Fatima / De Schepper, Maxim / Delorenzi, Mauro / Drukker, Caroline A / Glas, Annuska M / Green, Andrew R / Isnaldi, Edoardo / Eyfjörð, Jórunn / Khout, Hazem / Knappskog, Stian /

Krishnamurthy, Savitri / Lakhani, Sunil R / Langerod, Anita / Martens, John W M / McCart Reed, Amy E / Murphy, Leigh / Naulaerts, Stefan / Nik-Zainal, Serena / Nevelsteen, Ines / Neven, Patrick / Piccart, Martine / Poncet, Coralie / Punie, Kevin / Purdie, Colin / Rakha, Emad A / Richardson, Andrea / Rutgers, Emiel / Vincent-Salomon, Anne / Simpson, Peter T / Schmidt, Marjanka K / Sotiriou, Christos / Span, Paul N / Tan, Kiat Tee Benita / Thompson, Alastair / Tommasi, Stefania / Van Baelen, Karen / Van de Vijver, Marc / Van Laere, Steven / Van't Veer, Laura / Viale, Giuseppe / Viari, Alain / Vos, Hanne / Witteveen, Anke T / Wildiers, Hans / Floris, Giuseppe / Garg, Abhishek D / Smeets, Ann / Lambrechts, Diether / Biganzoli, Elia / Richard, François / Desmedt, Christine

Nature communications

2023 Volume 14, Issue 1, Page(s) 4418

Abstract: Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study investigates how the biology of untreated primary BC differs ... ...

Abstract	Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study investigates how the biology of untreated primary BC differs according to patients' body mass index (BMI) using data from >2,000 patients. We identify several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. We report evidence supporting an ageing accelerating effect of obesity at the genetic level. We show that BMI-associated differences in bulk transcriptomic profile are subtle, while single cell profiling allows detection of more pronounced changes in different cell compartments. These analyses further reveal an elevated and unresolved inflammation of the BC tumor microenvironment associated with obesity, with distinct characteristics contingent on the estrogen receptor status. Collectively, our analyses imply that obesity is associated with an inflammaging-like phenotype. We conclude that patient adiposity may play a significant role in the heterogeneity of BC and should be considered for BC treatment tailoring.
MeSH term(s)	Humans ; Female ; Breast Neoplasms/genetics ; Obesity/complications ; Obesity/genetics ; Molecular Biology ; Overweight ; Genomics ; Tumor Microenvironment
Language	English
Publishing date	2023-07-21
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-39996-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito